Business Context and Reporting Period
Company: Organon & Co.
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2026
Subject: Conclusion of an independent review by the Audit Committee regarding the timing of biosimilar purchases from a supplier in prior years.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a governance review rather than financial performance data.
Material Changes and Review Findings
- Review Outcome: The Audit Committee, assisted by outside counsel, completed its independent review of biosimilar purchase timing issues raised on February 11, 2026.
- Conduct Findings: The review found no evidence of improper conduct related to the transactions in question.
- Financial Impact: No matters were identified requiring adjustments to previously issued financial statements or SEC disclosures.
- Action Required: The review determined that no further action is required.
Guidance, Outlook, and Risks
- Reporting Status: The Company intends to timely file its Form 10-K for the year ended December 31, 2025.
- Forward-Looking Statements: The filing includes statements regarding the timing of the 2025 financial results and the 10-K filing. These are subject to risks including the completion of financial reporting processes and the review by the independent registered public accounting firm.
- Contingencies: No new contingencies or unusual items were identified by the Audit Committee review.
Key Facts for Investor Verification
- Verify the timely filing of the Form 10-K for the year ended December 31, 2025, as stated in the report.
- Confirm that no restatements of prior financial periods are issued following this review.
- Monitor subsequent filings for any updates regarding the biosimilar supplier relationship or procurement processes.